Crinetics Pharmaceuticals CRNX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -6,714.8%+25,899pp | -32,613.5%-27,066pp | -5,547.2%-2,003pp | -3,544.1%+6,447pp | |
| Net margin | -6,046.2%+22,674pp | -28,720.7%-23,375pp | -5,345.9%-1,885pp | -3,460.4%+6,525pp | |
| Returns | |||||
| Return on equity | -40.2%-8.1pp | -32%+18.1pp | -50.2%+0.4pp | -50.6%-7.6pp | |
| Return on invested capital | -50.4%-9.3pp | -41.2%+13.0pp | -54.2%+25.4pp | -79.6%+20.2pp | |
| Efficiency | |||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | |||||
| Current ratio | 12.3×-10.7× | 23×+10.0× | 13.1×+0.6× | 12.5×-9.1× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×-0.1× | 0.1×+0.1× | 0×0.0× | |
| Per Share | |||||
| Book value per share | $10.55-35.7% | $16.40+76.7% | $9.28+52.6% | $6.09-29.5% | |
| Valuation | |||||
| Market capitalization | $4.42B-6.8% | $4.74B+99.5% | $2.38B+141% | $984.73M-27.0% | |
| Price / sales | 574×-3,990× | 4,563.7×+3,971× | 592.3×+384× | 207.9×-1,044× | |
| Price / book | 4.5×+0.9× | 3.6×-0.8× | 4.4×+1.3× | 3.1×-1.0× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Crinetics Pharmaceuticals's profit margins?
- Crinetics Pharmaceuticals (CRNX) runs a 150.0% gross margin and a -3020.3% operating margin, with a -2747.2% net margin.
- Where do Crinetics Pharmaceuticals's ratios come from?
- Every ratio is computed from Crinetics Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
